Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8676305 | Revista Colombiana de Cardiología | 2017 | 6 Pages |
Abstract
Proprotein convertase subtilisin kexin 9 enzyme inhibitors are a novel therapeutic tool for the select group of very high risk patients who have not achieved LDL cholesterol goals. They have proven to have a powerful hypolipidemic effect and a good safety profile. Their use is expected to benefit patients by reducing their cardiovascular risk.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Rafael Campo,